摘要
目的:观察宫腔灌注液态浓缩生长因子对预防宫腔操作术后宫腔粘连的临床疗效。方法:收集2022年8月至2023年9月就诊于垫江县中医院妇科门诊人流患者共108例,选取随机数字法分为空白对照组、对照组、观察组各36例。宫腔操作术后三组患者予以口服复方大红袍止血片、康妇炎胶囊。在此基础上分别予以对照组宫腔注入赛必妥防粘连剂,观察组宫腔注入液态生长因子纤维蛋白(LPCGF)。三组患者均连续治疗2周。比较三组患者宫腔粘连的形成率、粘连程度、腹痛持续时长、阴道出血量及其持续时间、子宫内膜厚度、月经恢复时间及不良反应。结果:观察组在宫腔粘连的发生率和粘连分级上显著低于对照组和空白对照组(P P P > 0.05)。结论:宫腔灌注液态浓缩生长因子对预防宫腔操作术后宫腔粘连的临床疗效更佳,可显著改善临床症状,降低一系列的不良反应。Objective: To observe the clinical efficacy of uterine cavity instillation of liquid concentrated growth factor on the prevention of uterine adhesion after uterine operation. Methods: A total of 108 abortion patients who visited the gynecology outpatient clinic of Dianjiang County Hospital of Traditional Chinese Medicine from August 2022 to September 2023 were collected, and were divided into 36 cases each in the blank control group, the control group, and the observation group by the random number method. After intrauterine operation, the three groups of patients were orally administered compound Dahongpao hemostatic tablets and Kangwenyan capsules. On this basis, the control group was injected with Sebitol anti-adhesion agent into the uterine cavity, and the observation group was injected with liquid growth factor fibrin (LPCGF) into the uterine cavity. 2 weeks of continuous treatment were given to the patients in all three groups. The three groups were treated continuously for 2 weeks, and the rate of formation of uterine adhesions, the de
出处
《临床医学进展》
2024年第10期43-48,共6页
Advances in Clinical Medicine
